---
title: "Descartes-08 in Generalized myasthenia gravis: References"
description: "Reference list for the formulary evidence report on Descartes-08 in Generalized myasthenia gravis. 177 cited documents."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: References

<a id="references"></a>

## 5 References

1. [Alshekhlee et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19414721/)
2. [American Academy of Neurology myasthenic crisis quality measure](https://www.aan.com/practice/immunosuppressive-therapy-myasthenic-crisis-quality-measure)
3. [Antozzi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39862879/)
4. [argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_Hytrulo_WAC_Disclosure_for_Colorado_HCPs.pdf)
5. [argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_WAC_Disclosure_for_Colorado_HCPs.pdf)
6. [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)
7. [Benatar et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9780175/)
8. [Bkemv prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761333s008lbl.pdf)
9. [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/)
10. [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059507/)
11. [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)
12. [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)
13. [Cartesian Therapeutics 2026 outlook press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-highlights-recent-progress-and-outlines)
14. [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled)
15. [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm)
16. [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)
17. [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)
18. [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)
19. [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)
20. [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)
21. [Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024)](https://pmc.ncbi.nlm.nih.gov/articles/instance/13004676/bin/41591_2025_4171_MOESM1_ESM.pdf)
22. [Cartesian Therapeutics MGFA 2024 presentation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-presentation-results-phase-2b)
23. [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)
24. [Cartesian Therapeutics phase 2b topline results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-topline-results-phase)
25. [Cartesian Therapeutics phase 2b updated results press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-positive-updated-results-phase)
26. [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)
27. [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine)
28. [Cartesian Therapeutics second quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-second-quarter-2026-financial)
29. [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment)
30. [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)
31. [Cavalcante et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11187261/)
32. [Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026)](https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and)
33. [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)
34. [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)
35. [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/)
36. [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)
37. [ClinicalTrials.gov NCT04146051](https://clinicaltrials.gov/study/NCT04146051)
38. [ClinicalTrials.gov NCT06193889](https://clinicaltrials.gov/study/NCT06193889)
39. [ClinicalTrials.gov NCT06359041](https://clinicaltrials.gov/study/NCT06359041)
40. [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)
41. [ClinicalTrials.gov NCT06799247 record version 16](https://clinicaltrials.gov/study/NCT06799247?tab=history&a=16)
42. [ClinicalTrials.gov NCT07089121](https://clinicaltrials.gov/study/NCT07089121)
43. [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/)
44. [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)
45. [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)
46. [Dewilde et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12178031/)
47. [Di et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/)
48. [Dodd et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12224225/)
49. [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)
50. [Engel-Nitz et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29486521/)
51. [Epysqli prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761340s024lbl.pdf)
52. [EU Clinical Trials Information System 2024-520355-25-00](https://euclinicaltrials.eu/ctis-public/view/2024-520355-25-00)
53. [FDA news release on CAR T cell REMS elimination (2025)](https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)
54. [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722)
55. [FDA safety communication on CAR T cell REMS elimination (2025)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)
56. [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)
57. [Furqan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372811/)
58. [Gelinas et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35486970/)
59. [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)
60. [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)
61. [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)
62. [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)
63. [Granit et al. supplementary appendix (2023)](https://www.cartesiantherapeutics.com/wp-content/uploads/Supplementary-Appendix-rCAR-T-in-myasthenia-The-Lancet-Neurology.pdf)
64. [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)
65. [Greco et al. (2026)](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913%2826%2900249-3/fulltext)
66. [Grob et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18059039/)
67. [Gronseth et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32213645/)
68. [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)
69. [Grover et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42839213/)
70. [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)
71. [Gusovsky Chevalier et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11874732/)
72. [Gwathmey et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13409125/)
73. [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)
74. [Haghikia et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37977704/)
75. [Harris et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447171/)
76. [Hegelmaier et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13138368/)
77. [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)
78. [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)
79. [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)
80. [Howard (2018)](https://pubmed.ncbi.nlm.nih.gov/29266249/)
81. [Howard et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29066163/)
82. [Howard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34146511/)
83. [Howard et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059508/)
84. [Howard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11579873/)
85. [Howard et al. (2026)](https://www.cartesiantherapeutics.com/wp-content/uploads/092926_Descar_MGFA_Poster_Q10_CF.pdf)
86. [Huang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255718/)
87. [Hughes et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10520715/)
88. [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)
89. [ICER multiple myeloma final evidence report (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Unredacted_112222.pdf)
90. [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)
91. [Jackson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9837342/)
92. [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)
93. [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)
94. [Jagannath et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10260711/)
95. [Jiang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41319378/)
96. [Jul Jarbæk Nielsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40460351/)
97. [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)
98. [Katzberg et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24810970/)
99. [Khateb et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12116355/)
100. [Klygefa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761488s000lbl.pdf)
101. [Kumar and Kim (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13155473/)
102. [Kumar et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396046/)
103. [Kusner et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3531867/)
104. [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)
105. [Li et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41104507/)
106. [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/)
107. [Lin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7785573/)
108. [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/)
109. [Lyman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7136832/)
110. [Managed Healthcare Executive eculizumab biosimilars article (2025)](https://www.managedhealthcareexecutive.com/view/bkemv-and-epysqli-two-biosimilars-of-soliris-are-now-available)
111. [Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025)](https://www.managedhealthcareexecutive.com/view/fda-approves-uplizna-for-chronic-inflammatory-condition-igg4-rd)
112. [Manolopoulos et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522184/)
113. [Massachusetts Executive Office of Health and Human Services Administrative Bulletin 24-19 (2024)](https://www.mass.gov/doc/administrative-bulletin-24-19-101-cmr-32000-clinical-laboratory-services-2024-cpt-code-updates-effective-january-1-2024-0/download)
114. [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)
115. [Meisel et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13093530/)
116. [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)
117. [Mestinon prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92)
118. [Motte et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697115/)
119. [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)
120. [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)
121. [Myasthenia Gravis Foundation of America](https://myasthenia.org/wp-content/uploads/Portals/0/MGFA%20Classification.pdf)
122. [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)
123. [Narayanaswami et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400517/)
124. [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)
125. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-anti-bcma-car-mrna-transfected-cd8-t-lymphocytes)
126. [NCI Thesaurus (2026)](https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C156706)
127. [Nowak et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40202593/)
128. [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)
129. [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12577723/)
130. [Pesa et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41455461/)
131. [Pesa et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/43001852/)
132. [Pharmaceutical Technology Descartes-08 net present value page (2024)](https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-net-present-value/)
133. [pharmaphorum Imaavy approval article (2025)](https://pharmaphorum.com/news/jjs-swiss-army-knife-drug-gets-first-fda-approval)
134. [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)
135. [Pujades-Rodríguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089002/)
136. [Qi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832025/)
137. [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)
138. [Ribeiro et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40953960/)
139. [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)
140. [Rousseff (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8073361/)
141. [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)
142. [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/)
143. [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)
144. [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)
145. [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/)
146. [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)
147. [Smith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550228/)
148. [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/)
149. [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)
150. [Suh et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3670444/)
151. [Suzuki et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42275909/)
152. [Tian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018773/)
153. [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)
154. [Ting et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11906949/)
155. [Tse et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41422493/)
156. [UCB RYSTIGGO pricing information (2025)](https://www.ucb-usa.com/Sustainability/Affordability/RYSTIGGO-Pricing-Info)
157. [UCB ZILBRYSQ pricing information (2026)](https://www.ucb-usa.com/Sustainability/Affordability/ZILBRYSQ-Pricing-Info)
158. [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)
159. [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)
160. [Vinciguerra et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10526522/)
161. [Vissing et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7320935/)
162. [Vu et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319212/)
163. [Vu et al. (2025)](https://www.cartesiantherapeutics.com/wp-content/uploads/NMSG-Poster_09.26.25.pdf)
164. [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)
165. [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)
166. [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)
167. [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)
168. [Wolfe et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5189669/)
169. [Wolfe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6774753/)
170. [Wong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12538365/)
171. [Wong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42167622/)
172. [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11263250/)
173. [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)
174. [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)
175. [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/)
176. [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)
177. [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
